CN112638898B - 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 - Google Patents

杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 Download PDF

Info

Publication number
CN112638898B
CN112638898B CN201980056968.7A CN201980056968A CN112638898B CN 112638898 B CN112638898 B CN 112638898B CN 201980056968 A CN201980056968 A CN 201980056968A CN 112638898 B CN112638898 B CN 112638898B
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
independently
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980056968.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112638898A (zh
Inventor
蒂洛·福肯
让-克里斯托夫·安德烈斯
克里斯汀·尼科尔·伯福德
克里斯托夫·马丁·德纳德
迈克尔·爱德华·格里伍德
贾琦
弗纳·亚历山大·洛夫斯特兰德
史蒂文·西格蒙德·韦索洛斯基
迈克尔·斯科特·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CN112638898A publication Critical patent/CN112638898A/zh
Application granted granted Critical
Publication of CN112638898B publication Critical patent/CN112638898B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980056968.7A 2018-08-31 2019-08-29 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 Active CN112638898B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725960P 2018-08-31 2018-08-31
US62/725,960 2018-08-31
PCT/US2019/048900 WO2020047312A1 (en) 2018-08-31 2019-08-29 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Publications (2)

Publication Number Publication Date
CN112638898A CN112638898A (zh) 2021-04-09
CN112638898B true CN112638898B (zh) 2024-04-09

Family

ID=67953871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056968.7A Active CN112638898B (zh) 2018-08-31 2019-08-29 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途

Country Status (7)

Country Link
US (1) US10752623B2 (https=)
EP (1) EP3844158A1 (https=)
JP (1) JP7383012B2 (https=)
CN (1) CN112638898B (https=)
CA (1) CA3104913A1 (https=)
MA (1) MA53488A (https=)
WO (1) WO2020047312A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3458449T3 (pl) 2016-05-20 2025-06-23 Xenon Pharmaceuticals Inc. Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
US20250034108A1 (en) * 2023-07-07 2025-01-30 Novartis Ag Sodium channel blockers
CN117510431A (zh) * 2023-11-08 2024-02-06 浙江雅辰药物科技股份有限公司 一种异噻唑-3-酮及其衍生物、合成方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863785A (zh) * 2003-08-08 2006-11-15 沃泰克斯药物股份有限公司 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
WO2010026365A1 (en) * 2008-09-02 2010-03-11 University Of Dundee N-myristoyl transferase inhibitors
CN101883760A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的杂芳基酰胺类
CN103119045A (zh) * 2010-08-20 2013-05-22 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
CN104024251A (zh) * 2011-10-31 2014-09-03 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
CN104718188A (zh) * 2012-05-22 2015-06-17 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
CN106255679A (zh) * 2014-02-27 2016-12-21 默克专利有限公司 用作na v通道抑制剂的杂环化合物及其用途
WO2017201468A1 (en) * 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN107690281A (zh) * 2014-10-06 2018-02-13 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2018042316A1 (en) * 2016-08-29 2018-03-08 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2018106284A1 (en) * 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN112930175A (zh) * 2018-07-27 2021-06-08 泽农医药公司 治疗癫痫的方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
EP0981327B1 (en) 1997-05-07 2002-11-06 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP2009513523A (ja) 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
US8202861B2 (en) 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
JP2008524244A (ja) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
NZ593074A (en) 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
EP2054385A2 (en) 2006-08-15 2009-05-06 F. Hoffmann-Roche AG Phenyl, pyridine and quinoline derivatives
US7968556B2 (en) 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8853250B2 (en) 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
RU2011103451A (ru) 2008-07-01 2012-08-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
JP2014532660A (ja) 2011-10-28 2014-12-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
KR102038607B1 (ko) 2012-10-15 2019-10-30 주식회사 대웅제약 소디움 채널 차단제, 이의 제조방법 및 이의 용도
EP2911668A4 (en) 2012-10-26 2016-07-20 Merck Sharp & Dohme BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS
JP2015535252A (ja) 2012-10-26 2015-12-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014201173A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
JP6407285B2 (ja) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子
UA120353C2 (uk) 2013-09-10 2019-11-25 Хромоселл Корпорейшн Модулятори натрієвого каналу для лікування болю і діабету
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
AU2014370407B2 (en) 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
KR102412146B1 (ko) * 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
WO2016177340A1 (zh) 2015-05-05 2016-11-10 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
US10519147B2 (en) 2015-12-18 2019-12-31 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
US10668067B2 (en) 2016-07-20 2020-06-02 Amgen Inc. Pyridine sulfonamides
WO2018093694A1 (en) 2016-11-17 2018-05-24 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863785A (zh) * 2003-08-08 2006-11-15 沃泰克斯药物股份有限公司 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
CN101883760A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的杂芳基酰胺类
WO2010026365A1 (en) * 2008-09-02 2010-03-11 University Of Dundee N-myristoyl transferase inhibitors
CN103119045A (zh) * 2010-08-20 2013-05-22 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
CN104024251A (zh) * 2011-10-31 2014-09-03 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
CN104718188A (zh) * 2012-05-22 2015-06-17 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
CN106255679A (zh) * 2014-02-27 2016-12-21 默克专利有限公司 用作na v通道抑制剂的杂环化合物及其用途
CN107690281A (zh) * 2014-10-06 2018-02-13 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2017201468A1 (en) * 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2018042316A1 (en) * 2016-08-29 2018-03-08 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2018106284A1 (en) * 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN112930175A (zh) * 2018-07-27 2021-06-08 泽农医药公司 治疗癫痫的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chapter 15-Molecular Variations Based on Isosteric Replacements;Paola Ciapetti and Bruno Giethlen;The Practice of Medicinal Chemistry (THIRD EDITION);290-342 *

Also Published As

Publication number Publication date
JP2021535137A (ja) 2021-12-16
CN112638898A (zh) 2021-04-09
MA53488A (fr) 2021-12-08
US20200071313A1 (en) 2020-03-05
US10752623B2 (en) 2020-08-25
JP7383012B2 (ja) 2023-11-17
EP3844158A1 (en) 2021-07-07
WO2020047312A1 (en) 2020-03-05
CA3104913A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
CN112638898B (zh) 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
US11299490B2 (en) Benzenesulfonamide compounds and their use as therapeutic agents
CN112638879B (zh) 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途
HK40049688A (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
HK40005248A (en) Benzenesulfonamide compounds and their use as therapeutic agents
HK40005248B (en) Benzenesulfonamide compounds and their use as therapeutic agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant